Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01040156

Enrollment

Unknown

Registered

2009-12-29

Start date

2008-08-31

Completion date

2009-12-31

Last updated

2009-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Aspergillosis, Systemic Candidiasis

Brief summary

Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Inclusion criteria

* Pediatric patients under the age of 18 years * Pediatric patients after HSCT treated with caspofungin * Pediatric patients after HSCT treated with liposomal amphotericin

Exclusion criteria

* Pediatric patients with uncontrolled hematological malignancies * Pediatric patients with IFI at start of HSCT

Countries

Germany

Outcome results